Research ArticleCancer

Therapeutic targeting of KSP in preclinical models of high-risk neuroblastoma

See allHide authors and affiliations

Science Translational Medicine  23 Sep 2020:
Vol. 12, Issue 562, eaba4434
DOI: 10.1126/scitranslmed.aba4434

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Blasting away neuroblastoma

Neuroblastoma is a childhood cancer that can be difficult to treat and is often associated with poor outcomes. To identify therapeutic candidates for this cancer, Hansson et al. screened a large variety of compounds using tumor organoids derived from patients with high-risk neuroblastoma. One of the top hits in this screen was an inhibitor of kinesin spindle protein. The authors demonstrated that this protein is a key dependency in neuroblastoma and that inhibiting it causes numerous abnormalities during cell division, resulting in tumor cell death. In vivo treatment with this inhibitor showed promising results in orthotopic patient-derived xenograft models, including aggressive types associated with poor prognosis.

View Full Text

Stay Connected to Science Translational Medicine